Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, Volume 119, Issue 12, 2537 - 2548

Silva, Rufino et al. The SECURE Study. Ophthalmology, Volume 120, Issue 1, 130 - 139

Ophthalmology. 2020 Jan;127(1):72-84.

 ClinicalTrials.gov Identifier: NCT03823287

https://clinicaltrials.gov/ct2/show/NCT03622580 

• kedvező egy éves eredmények: https://www.roche.com/media/releases/med-cor-2020-12-21.htm

TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2

• https://clinicaltrials.gov/ct2/show/NCT03150589

• A kutatás eredményei: 

  • Neil M Bressler, Miroslav Veith, Jan Hamouz, Jan Ernest,  Dominik Zalewski, Jan Studnička, Attila Vajas, András Papp, Gabor Vogt, James Luu, Veronika Matuskova, Young Hee Yoon, Tamás Pregun, Taehyung Kim, Donghoon Shin, Inkyung Oh, Hansol Jeong, Mercy Yeeun Kim, Se Joon Woo: Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol 2023;107:384–391. doi:10.1136/bjophthalmol-2021-319637 (Full text)

  • Se Joon Woo, MD, PhD; Miroslav Veith, MD; Jan Hamouz, MD; Jan Ernest, MD, PhD; Dominik Zalewski, MD, PhD; Jan Studnička, MD, PhD; Attila Vajas, MD; Andras Papp, MD, PhD; Vogt Gabor, MD, PhD; James Luu, MD; Veronika Matuskova, MD, PhD; Young Hee Yoon, MD, PhD; Tamás Pregun, MD; Taehyung Kim, MSc; Donghoon Shin, MD, PhD; Neil M. Bressler, MD: Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021;139(1):68-76. doi:10.1001/jamaophthalmol.2020.5053 (fulltext)

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients. Press release, Allergan, 2020 Mar 05

ClinicalTrials.gov Identifier: NCT03850782

• Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension. Press release, Aerie, 03/12/2019

• ClinicalTrials.gov Identifier: NCT03284853

• ClinicalTrials.gov Identifier: NCT01298700

• https://clinicaltrials.gov/ct2/show/NCT00351611

 ClinicalTrials.gov Identifier: NCT03805100)

ClinicalTrials.gov Identifier: NCT03364153

https://clinicaltrials.gov/ct2/show/NCT03362190 

Az egyik kutatás eredményéről itt olvashatnak: https://www.aaojournal.org/article/S0161-6420(20)30845-9/fulltext?dgcid=raven_jbs_aip_email#supplementaryMaterial 

Arshad M Khanani, MD,  Sunil S Patel, MD, Prof Giovanni Staurenghi, MD,  Prof Ramin Tadayoni, MD, Carl J Danzig, MD, David A Eichenbaum, MD et al. on behalf of theGATHER2 trial investigators:  Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet,  VOLUME 402, ISSUE 10411, P1449-1458, OCTOBER 21, 2023  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01583-0/abstract

ClinicalTrials.gov Identifier: NCT03610646

Bressler SB, Barve A, Ganapathi PC, et al. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. JAMA Ophthalmol. Published online September 12, 2024. doi:10.1001/jamaophthalmol.2024.3458